WHO sets new global standard for child-friendly cancer drugs, paving way for industry innovation

Each year, an estimated 400,000 children and adolescents develop cancer, yet survival rates remain below 30% in most low- and middle-income countries (LMICs) compared with over 80% in high-income settings. A significant barrier is the lack of age-appropriate medicines. 

Click here to access the article.